Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Danavorexton in Obstructive Sleep Apnea
NCT05180890Phase 1Completed
- Sponsor
- Takeda
- Start
- Mar 2022
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of danavorexton in obstructive sleep apnea (OSA) (3 arms), sponsored by Takeda. Primary endpoint: Treatment-emergent Adverse Events up to 41 days. Started Mar 2022; status: completed.
02
Drugs
danavorexton
03
Conditions
obstructive sleep apnea (OSA)
Beyond the preview
Go deeper on NCT05180890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05180890.